Rigel Pharma (RIGL) to Present Data on TAVALISSE (fostamatinib disodium) Phase 3 at EHA Conference on 6/24
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that data from its FIT Phase 3 clinical program evaluating the safety and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
